Compare International Business Machines Corp (IBM) vs 10X Genomics Inc (TXG) Price & Performance

IBM's stock trades at $210.5, down 1.02% over the past day, amid a bearish technical signal and recent volatility following a pre-announced Q2 2026 earnings miss. The company shows strong profitability with a net income margin of 15.61% and has beaten earnings estimates in three of the last four quarters. However, negative cash flow in 2025 and a 25% stock drop on July 14, 2026, due to lowered growth guidance have heightened investor concerns. Analyst consensus remains moderately positive with a $282.47 price target, but legal investigations into the guidance cut add uncertainty.

The outlook is cautious; solid fundamentals and a high dividend yield offer value, but execution risks and slowing revenue growth pose significant headwinds. Investment opportunity hinges on IBM's ability to stabilize performance and meet future earnings expectations, while key risks include ongoing legal scrutiny and competitive pressures in the technology sector.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.